PTC
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
PTC Inc. operates as a global provider of software and services, with its market presence extending across the Americas, Europe, and the Asia Pacific regions. The company's business is organized into ...
Latest News
6 hours ago · marketbeat.com
PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance DatePTC Therapeutics NASDAQ: PTCT expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug's strong first year of sales can be sustained.
8 days ago · globenewswire.com
Eos SENOLYTIX's PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International ConferenceData to highlight PTC-2105's attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos's lead clinical candidate in development for elderly patients with Sarcopenia and Sarcopenic Obesity Eos's merger with Pulmatrix, Inc. anticipated to close in Q4 2026, subject to Nasdaq listing approval and customary closing conditions HOUSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”), a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today announced it will present new data from a pre-clinical study of its lead MitoXcel™ geropeptide, PTC-2105, at the 19th Sarcopenia, Cachexia & Wasting Disorders International Conference (SCWD), taking place December 10-12, 2026 in Washington, D.C. Eos's presentation was recently upgraded from a poster presentation to a plenary presentation in the Rapid Fire Abstract Session to be held on December 11, 2026, at 9:35 am.
10 days ago · businesswire.com
PTC Stock Alert: Halper Sadeh LLC is Investigating Whether PTC Inc. is Obtaining a Fair Price for its ShareholdersNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of PTC Inc. (NASDAQ: PTC) to Schneider Electric for $205.00 per share in cash.Halper Sadeh encourages PTC shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether PTC and its board of directors violated the federal securiti.
11 days ago · zacks.com
PTC Inc. (PTC) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesWhile the top- and bottom-line numbers for PTC Inc. (PTC) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
12 days ago · zacks.com
PTC Q4 Earnings & Revenues Beat Estimates, ARR Growth StrongPTC's Q4 fiscal 2026 earnings and revenues beat estimates, while ARR growth remain strong despite revenue declines and divestiture-related pressures.
12 days ago · zacks.com
PTC Inc. (PTC) Surpasses Q4 Earnings and Revenue EstimatesPTC Inc. (PTC) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $3.47 per share a year ago.
12 days ago · prnewswire.com
PTC ANNOUNCES FOURTH FISCAL QUARTER AND FULL FISCAL YEAR 2026 RESULTSStrategic focus on Intelligent Product Lifecycle vision BOSTON, Nov. 4, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its fourth fiscal quarter and full fiscal year ended September 30, 2026. Fourth Fiscal Quarter and Full Fiscal Year 2026 Key Operating and Financial Metrics 1 $ in millions, except per share amounts Q4'26 Q4'25 YoY Change As reported ARR excluding divestedbusinesses2 $2,508 $2,320 8 % Constant currency ARR excluding divestedbusinesses (FY'26 Plan FX rates3) $2,545 $2,320 9.7 % Operating cash flow $475 $104 (55 %) Free cash flow $385 $100 (63 %) Revenue4 $673 $894 (25%)6 Operating margin4 32 % 49 % (1,690 bps) Non-GAAP operating margin4 46 % 59 % (1,320 bps) Earnings per share4 $1.44 $2.88 (50 %) Non-GAAP earnings per share4 $2.03 $3.41 (40 %) 1 The definitions of our operating and non-GAAP financial measures and reconciliations of non-GAAP financial measures to comparable GAAP measures are included below and in the reconciliation tables at the end of this press release.
14 days ago · seekingalpha.com
PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already KnowsPTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines offset gains; Q4 and 2027 results are key inflection points. PTCT's guidance has been consistently conservative, with actual quarterly sales repeatedly beating top-end forecasts.
14 days ago · prnewswire.com
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase ProgramWARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's outstanding shares of common stock, subject to market conditions.
15 days ago · zacks.com
PTC Heads Into Q4 Earnings as Schneider Buyout Looms: What's in Store?PTC's fiscal Q4 results hinge on ARR growth, AI adoption and cash flow momentum, while its pending $22.6 billion acquisition by Schneider Electric adds a key dimension.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PTC